Navigation Links
Lupus Research Institute Highly Encouraged by Benlysta(TM) Trial Results
Date:7/19/2009

First Phase 3 Lupus Drug Trial in Decades to Show Effectiveness

NEW YORK, July 20 /PRNewswire-USNewswire/ -- The Lupus Research Institute (LRI) and its National Coalition of state and local organizations congratulate Human Genome Sciences (HGS) and GlaxoSmithKline on the highly promising results of this landmark clinical trial of Benlysta(TM) (belimumab) for people with systemic lupus.

"We are very hopeful that we now are strongly on our way to the first new treatment for lupus in 50 years," said LRI President, Margaret G. Dowd. "We look forward to the impact that a new drug for lupus will have on the lives of the 1.5 million Americans, and millions more worldwide, who suffer from this devastating autoimmune illness."

"This is a major advance for patients, families, and physicians--the entire lupus community!" said Richard Furie, MD, chief of the division of rheumatology and allergy-clinical rheumatology at North Shore-LIJ Health System in New York. "There is no doubt that a drug approval will foster further drug development and additional discoveries."

In the double-blind, placebo-controlled, multi-center trial, known as BLISS-52, both dose levels of Benlysta(TM) plus standard of care were more effective than a placebo plus standard of care in people with serologically active systemic lupus. A total of 867 participants at 90 clinical sites in 13 countries, primarily in Asia, South America and Eastern Europe, were enrolled in the trial.

"This is the first drug shown to be effective in ameliorating the signs and symptoms of lupus in decades," said Daniel J. Wallace, MD, clinical professor of medicine at the David Geffen School of Medicine at UCLA. "It represents a breakthrough for finally utilizing a methodology that enables researchers to demonstrate disease improvement. This will benefit lupus patients and their doctors."'/>"/>

SOURCE Lupus Research Institute
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. New Risk Gene for Rheumatoid Arthritis and Lupus Opens Door to More Effective Treatments
2. Coley Pharmaceutical Group Diversifies Pipeline with First-in-Class TLR Antagonist for the Treatment of Systemic Lupus Erythematosus
3. Human Genome Sciences Reports Positive Data from Long-Term Treatment with LymphoStat-B(R) in Patients with Active Systemic Lupus Erythematosus
4. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
5. Steps Toward Stopping Autoimmune Disease: International Consortium Identifies Genes Linked to Lupus
6. Rigels R788 Slows Progression of Murine Lupus in Preclinical Studies
7. Statement From the Lupus Foundation of America Regarding the Release of Top-Line Results From a Study of Rituxan for the Treatment of Lupus
8. Lupus Under the Spotlight: U.S. Congress Shows Support for Womens Health Issues
9. Human Genome Sciences Reports Positive Long-Term Data for LymphoStat-B in Patients With Active Systemic Lupus Erythematosus
10. Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus
11. Study Results Show Epratuzumab Provided Clinically Meaningful Reduced Disease Activity in Patients With Lupus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... 27, 2015   Cypher Genomics, Inc., ... data showing that, compared to a panel of ... highly equivalent interpretations of whether certain genetic abnormalities ... in a fraction of the time. Cypher,s Mantis ... comprehensive genetic analysis in non-invasive prenatal testing (NIPT) ...
(Date:3/27/2015)... , March 27, 2015 XRpro Sciences, ... drug discovery and development services which features high ... pharmaceutical industry, announced financial results for the year ... C.  Tyson, Chairman of XRpro Sciences commented, "We ... transition from development stage to commercial stage in ...
(Date:3/27/2015)... DALLAS , March 27, 2015 ... Market by Product (Diagnostic Catheter (Conventional, Advanced, Ultrasound), Ablation ... ICE, X-ray)) & Indication (AF, VT, WPW) - Global ... Market is expected to reach around ~$4.73 Billion by ... forecast period 2014 to 2019. Browse ...
Breaking Medicine Technology:New Data at ACMG Shows Cypher's Software Can Automate Interpretation of Genetic Variants to Advance Non-invasive Prenatal Testing 2New Data at ACMG Shows Cypher's Software Can Automate Interpretation of Genetic Variants to Advance Non-invasive Prenatal Testing 3XRpro Sciences Announces Fiscal 2014 Financial Results 2XRpro Sciences Announces Fiscal 2014 Financial Results 3XRpro Sciences Announces Fiscal 2014 Financial Results 4Electrophysiology (EP) Market Worth $4.73 Billion by 2019 2Electrophysiology (EP) Market Worth $4.73 Billion by 2019 3Electrophysiology (EP) Market Worth $4.73 Billion by 2019 4
... HARBIN, China , ... Sheets: RHGP) ("Renhuang" or the "Company"), a,developer, manufacturer ... medicines ("TCM"), today announced,that the Company successfully exhibited ... Harbin International Economic,and Trade Fair ("Harbin Trade Fair") ...
... Mass. , July 1 Shire plc (LSE: ... today announced positive data from its long-term extension to its ... alfa), the company,s enzyme replacement therapy for patients with type ... Annual European Working Group on Gaucher Disease (EWGGD) in ...
Cached Medicine Technology:Renhuang Pharmaceuticals Exhibits Siberian Ginseng Products at the 21st China Harbin International Economic and Trade Fair 2Renhuang Pharmaceuticals Exhibits Siberian Ginseng Products at the 21st China Harbin International Economic and Trade Fair 3Renhuang Pharmaceuticals Exhibits Siberian Ginseng Products at the 21st China Harbin International Economic and Trade Fair 4Data Presented at the European Working Group on Gaucher Disease Demonstrate Continuous Improvements in Bone Mineral Density for VPRIV(R) (Velaglucerase Alfa) Through 69 Months 2Data Presented at the European Working Group on Gaucher Disease Demonstrate Continuous Improvements in Bone Mineral Density for VPRIV(R) (Velaglucerase Alfa) Through 69 Months 3Data Presented at the European Working Group on Gaucher Disease Demonstrate Continuous Improvements in Bone Mineral Density for VPRIV(R) (Velaglucerase Alfa) Through 69 Months 4Data Presented at the European Working Group on Gaucher Disease Demonstrate Continuous Improvements in Bone Mineral Density for VPRIV(R) (Velaglucerase Alfa) Through 69 Months 5Data Presented at the European Working Group on Gaucher Disease Demonstrate Continuous Improvements in Bone Mineral Density for VPRIV(R) (Velaglucerase Alfa) Through 69 Months 6
(Date:3/28/2015)... 2015 Purity Products®, a leading ... the release of their revolutionary new weight loss ... randomized, double-blind, placebo-controlled clinical studies to be effective ... size. MuffinStop™ is a combination of two traditionally ... fused together to create one of the most ...
(Date:3/27/2015)... Red Deer, Alberta (PRWEB) March 27, 2015 ... had, until then, prevented her from working, Monica K. arrived ... day in the mending department quiet, defensive and scared. The ... Employment Placement & Support Services (EPSS) to offer jobs ... it does take patience and a willingness to begin with ...
(Date:3/27/2015)... York, NY (PRWEB) March 27, 2015 ... seeing more plastic surgery patients travel to the Dominican ... Medina. The plastic surgery clinic is turning the medical ... international cosmetic surgery patients — with trustworthy services becoming ... factor when selecting a plastic surgeon. Patients are not ...
(Date:3/27/2015)... San Jose, CA (PRWEB) March 27, 2015 ... last week’s 2015 GPU technology conference (GTC) , the ... to fight cancer and push the human lifespan well beyond ... Baltimore MD informatics company , is one of 12 ... , While other startups in the GTC Emerging ...
(Date:3/27/2015)... March 27, 2015 Endure Yoga is ... functional fitness athletes. This new program matches yoga poses ... for post-workout cool down. This program utilizes yoga to ... and mental focus. , Karen Lefurgy, competitive athlete ... yoga long before I started Crossfit® training, but quickly, ...
Breaking Medicine News(10 mins):Health News:Purity Products Releases Revolutionary New Weight Loss Product, MuffinStop™ 2Health News:Red Deer Uniforms Shop Celebrates 3rd Year Sewing Hope for the Challenged 2Health News:Red Deer Uniforms Shop Celebrates 3rd Year Sewing Hope for the Challenged 3Health News:Dominican Republic Plastic Surgery Provider Turning Medical Tourism Upside-Down 2Health News:Dominican Republic Plastic Surgery Provider Turning Medical Tourism Upside-Down 3Health News:InSilico Medicine, Inc. Stands Out from High Tech Startups at 2015 GPU Conference 2Health News:InSilico Medicine, Inc. Stands Out from High Tech Startups at 2015 GPU Conference 3Health News:Endure Yoga Introduces WOD Recovery Yoga 2
... The Center for ... with the flu (influenza). On average, the influenza virus leads to 20,000 to 40,000 American ... deaths by offering free flu shots . , ... Plano, TX (Vocus) September 12, 2009 -- Starting Monday, September 14th, the Plano location ...
... Hernandez, Ph.D., M.P.H.an assistant professor at the University of ... that body mass in younger and older adulthood, and ... man,s risk for prostate cancer. This risk varies among ... study published in Cancer Epidemiology, Biomarkers & Prevention ...
... , TAMPA, Fla. and SAN FRANCISCO, Sept. ... agreement to roll out Demandforce D3, a web-based patient communications ... in Florida and Georgia. Coast Dental, the leading dental provider ... pilot. , , Coast Dental integrated the ...
... NEW YORK, Sept. 11 Duane Reade Holdings Inc., ... as the Local Presenting Sponsor of the 2009 Komen New York ... foundation, The Duane Reade Charitable Foundation, have raised $330,000 to increase ... find a cure. This marks the third year that Duane Reade ...
... , LIONVILLE, Pa., Sept. 11 ... that Donald E. Morel, Jr., Ph.D., Chairman and Chief Executive Officer, ... 7th Annual Best Ideas Conference 2009, being held September 16-17, 2009 ... the UBS Global Life Sciences Conference, being held September 21-23, 2009 ...
... ROCHESTER, Minn., Sept. 11 Mayo Clinic researchers ... may help them diagnose cardiac infections without an invasive exam. ... on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco. , ... ) , , Endocarditis -- an infection ...
Cached Medicine News:Health News:H1N1 frenzy may allow regular flu to be more deadly than ever 2Health News:University of Hawaii at Manoa CRCH scientists report adulthood body size associated with cancer risk 2Health News:Coast Dental Deploys Demandforce D3 Communications Platform 2Health News:New Yorkers Help Duane Reade Increase Support of the 19th Annual Komen New York City Race For The Cure(R) 2Health News:New Yorkers Help Duane Reade Increase Support of the 19th Annual Komen New York City Race For The Cure(R) 3Health News:West to Present at Two Upcoming Investor Conferences 2Health News:Artificial Intelligence Helps Diagnose Cardiac Infections 2Health News:Artificial Intelligence Helps Diagnose Cardiac Infections 3
... the examination of the anatomical conditions in the ... expanse and form of the iridocorneal angle can ... beam. The slit lamp 900, with its swivelling ... an assessment of the expanse of the entire ...
An antegrade femoral nail....
... WH, the latest in the Magnes line of ... and its full cortical coverage, provides the highest ... allowing study of a wide range of neuronal ... choice of detector configurations and can be equipped ...
... stimulation is a non-invasive and painless method ... system. Cadwell Laboratories manufactures two magnetic stimulation ... Magnetic Stimulator (HSMS). The Hight ... stimulation rates up to 25 Hz at ...
Medicine Products: